Susan Gasser bientôt à la tête de l'Institut Friedrich Miescher
| Source: Novartis Pharma AG
Recommended Reading
-
Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low...
Read More -
Novartis retains first place ranking among 20 sector peers for efforts to improve access to medicinesFirst company to achieve No. 1 rank across all Technical Areas since Index began in 2008, achieving...
Read More